ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? - PubMed

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disease-modifying genes identified, etiology remains unexplained and treatment options remain limited for the majority of ALS patients. Various factors have contributed to the slow progress in understanding and developing therapeutics for this disease. Here,

ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Searc

saved by

• Srushti Ishwarkatti

related reading

• Research Areas - Svendsen Lab | Cedars-Sinaicedars-sinai.edu
• ALS - Wikipediaen.wikipedia.org
• Sonja W. Scholz, M.D., Ph.D. | Principal Investigators | NIH Intramural Research Programirp.nih.gov
• Blood biomarkers in ALS: challenges, applications and novel frontiers - PMCncbi.nlm.nih.gov
• Staging of brain pathology related to sporadic Parkinson's disease - PubMedpubmed.ncbi.nlm.nih.gov
• Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand? - PubMedpubmed.ncbi.nlm.nih.gov
• Protein Destabilization as a Common Factor in Diverse Inherited Disorders - PubMedpubmed.ncbi.nlm.nih.gov
• RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia - PubMedpubmed.ncbi.nlm.nih.gov
• Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness - PubMedpubmed.ncbi.nlm.nih.gov
• GBA Variants and Parkinson Disease: Mechanisms and Treatmentspmc.ncbi.nlm.nih.gov
• Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis - Parkinson’s Disease - NCBI Bookshelfncbi.nlm.nih.gov
• The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com